Publications

Monomeric CH3: A Small, Stable Antibody Domain with Therapeutic Promise

By Ashley DeVine, Staff WriterPlatinum Highlight Icon

Antibody domains are emerging as promising biopharmaceuticals because of their relatively small size compared to full-sized antibodies, which are too large to effectively penetrate tumors and bind to sterically restricted therapeutic targets.

In an article published in The Journal of Biological Chemistry, Tianlei Ying, Ph.D., Dimiter Dimitrov, Ph.D., and their colleagues in the Protein Interactions Group, Cancer and Inflammation Program, Center for Cancer Research, reported their design of a novel antibody domain, monomeric CH3 (mCH3).

Tags: 

Platinum Publications as of March 6, 2014

Platinum Publications are selected from articles by NCI at Frederick scientists published in 21 prestigious science journals. This list represents new publications generated from PubMed as of the date shown above.

Articles designated as Platinum Highlights are noteworthy articles selected by Dr. Craig Reynolds, associate director, National Cancer Institute, from among the most recently published Platinum Publications.

Tags: 

Platinum Publications as of December 3, 2013

Platinum Publications are selected from articles by NCI at Frederick scientists published in 21 prestigious science journals. This list represents new publications generated from PubMed as of the date shown above.

Articles designated as Platinum Highlights are noteworthy articles selected by Dr. Craig Reynolds, associate director, National Cancer Institute, from among the most recently published Platinum Publications.

Tags: 

Gut Microorganisms Found Necessary for Successful Cancer Therapy

Group photo of four scientists

Platinum Highlight Icon

By Nancy Parrish, Staff Writer

Humans play host to trillions of microorganisms that help our bodies perform basic functions, like digestion, growth, and fighting disease. In fact, bacterial cells outnumber the human cells in our bodies by 10 to 1.1

The tens of trillions of microorganisms thriving in our intestines are known as gut microbiota, and those that are not harmful to us are referred to as commensal microbiota. In a recent paper in Science, NCI scientists described their discovery that, in mice, the presence of commensal microbiota is needed for successful response to cancer therapy.

Tags: 

Pages

Subscribe to Publications